Royalty Pharma EBITDA Margin 2019-2025 | RPRX

Royalty Pharma ebitda margin for the quarter ending March 31, 2025 was 84.81%.

  • Royalty Pharma average ebitda margin for 2024 was 53.39%, a 68.74% increase from 2023.
  • Royalty Pharma average ebitda margin for 2023 was 31.64%, a 26.04% increase from 2022.
  • Royalty Pharma average ebitda margin for 2022 was 42.78%, a 40.26% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Royalty Pharma EBITDA Margin 2019-2025 | RPRX

  • Royalty Pharma average ebitda margin for 2024 was 53.39%, a 68.74% increase from 2023.
  • Royalty Pharma average ebitda margin for 2023 was 31.64%, a 26.04% increase from 2022.
  • Royalty Pharma average ebitda margin for 2022 was 42.78%, a 40.26% decline from 2021.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.
Related Stocks
Company NameMarket
Cap
American Express (AXP)$176.6B
Blackstone (BX)$95.1B
Brookfield Asset Management (BAM)$79.6B
Moody's (MCO)$76.4B
Coinbase Global (COIN)$44.4B
Orix Corp Ads (IX)$22.5B
Synchrony Financial (SYF)$18.6B
BB Seguridade Participacoes SA (BBSEY)$14.1B
SoFi Technologies (SOFI)$12B
Houlihan Lokey (HLI)$10.8B
Globe Life (GL)$10.1B
Daiwa Securities Group (DSEEY)$8.9B
Jefferies Financial Group (JEF)$8.8B
SouthState (SSB)$8.6B
XP (XP)$7.7B
Freedom Holding (FRHC)$7.6B
Brookfield Wealth Solutions (BNT)$7.2B
Blue Owl Capital (OBDC)$7.1B
Virtu Financial (VIRT)$6B
StepStone Group (STEP)$5.5B
Rithm Capital (RITM)$5.4B
Euronet Worldwide (EEFT)$4.1B
Lazard (LAZ)$4B
StoneX Group (SNEX)$3.9B
Upstart Holdings (UPST)$3.8B
Intercorp Financial Services (IFS)$3.6B
Abrdn (SLFPY)$3.5B
AXOS FINANCIAL, INC (AX)$3.4B
CI Financial (CIXXF)$3.2B
Burford Capital (BUR)$3B